Finance

Novo Nordisk to buy Prothena’s heart drug in deal worth up to $1.2 billion By Reuters

© Reuters. FILE PHOTO: Flags are seen outside Novo Nordisk headquarters in Copenhagen, Denmark, February 5, 2020. REUTERS/Jacob Gronholt-Pedersen/File Photo

(Reuters) – Danish drugmaker Novo Nordisk (NYSE:) will acquire U.S. drug developer Prothena Corp’s experimental heart therapy, PRX004, in a deal that could be worth up to $1.23 billion, the companies said on Monday.

The acquisition is in line with Novo’s strategy to diversify its core insulin portfolio that has been facing tough competition, prompting it to turn toward newer diabetes and obesity drugs to revive growth.

Under the agreement, Prothena will receive $100 million in upfront and near-term clinical milestone payments for PRX004, currently in a mid-stage trial.

Prothena in December had reported positive data from an early-stage trial of PRX004 to treat hereditary ATTR amyloidosis, a life-threatening genetic disease that affects the heart, nerves and other organs.

Novo Nordisk said it would focus on developing PRX004 for ATTR cardiomyopathy, a potentially fatal form of the disease characterized by a build-up of amyloid deposits in cardiac tissue.

The Danish firm in June last year had agreed to buy AstraZeneca (NASDAQ:) spin-off Corvidia Therapeutics for an initial $725 million to expand into cardiovascular disease treatments.

Prothena’s pipeline includes drugs being developed to treat several neurodegenerative diseases including Alzheimer’s disease and Parkinson’s as well as disorders like AL amyloidosis.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.


Most Related Links :
Business News Governmental News Finance News

Need Your Help Today. Your $1 can change life.

[charitable_donation_form campaign_id=57167]

Source link

Back to top button